Cannabis for Spasticity in Multiple Sclerosis

Exclusion Criteria

• •Preexisting pulmonary conditions, including poorly controlled asthma, chronic bronchitis, emphysema, bronchiectasis, and other significant pulmonary disorders
• •Preexisting cardiac conditions, including ischemic heart disease, congestive heart failure, and other significant cardiac disorders
• •Inability to abstain from tobacco or marijuana smoking, or use of alcohol or sedative or hypnotic medications during the duration of the study
• •Pre-existing dementia, mania, depression or schizophrenia or other poorly controlled psychiatric illness
• •Past history of abuse of recreational drugs, including marijuana and alcohol in the last 12 months
• •History of or currently meets DSM-IV criteria for dependence on cannabis
• •Use of cannabis, marijuana, or THC in the last four weeks
• •Preexisting dementia, mania, depression, or schizophrenia or other poorly controlled psychiatric illness
• •Exacerbation of MS within 30 days prior to screening visit
• •Current use of cyclophosphamide, mitoxantrone, or cladribine
• •Arthritis, bony and soft tissue disorders interfering with spasticity measures
• •Inability to provide informed consent
• •Recent cannabis use of more than twice per week one month prior to study entry
• •For females of child bearing potential, inability to comply with adequate contraception